IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world’s largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enhance the conduct of clinical research in obesity and related cardiometabolic trials.
With the combined strength of two best-in-class organizations, this collaboration accelerates even the most sophisticated clinical programs and ensures coordinated, end-to-end support to sponsors, regulators, payers, patients and the broader medical community. By establishing the full operational framework up front, from governance to data flow to site-level execution, IQVIA and DCRI are able to quickly establish momentum on clinical trials with active support for a successful submission and beyond.
“By combining IQVIA’s operational excellence and global reach with DCRI’s academic rigor, we are setting a new standard for prospective collaboration between life science service companies and academic research organizations to accelerate clinical trial planning and delivery in obesity and related therapeutic areas,” said Dr. Jeffrey Spaeder, chief medical and scientific officer, IQVIA. “Uniting our combined clinical strength and complementary capabilities enables us to maximize trial efficiency, accelerate timelines and ultimately bring impactful therapies to patients faster.”
With more than 120 obesity trials conducted and more than 90,000 patients enrolled, IQVIA has supported clinical development, including operations, labs and patient support, for every FDA‑approved GLP‑1 therapy to date. This experience gives sponsors entering obesity and metabolic research a proven foundation. The collaboration between IQVIA and DCRI is poised to drive meaningful improvements in patient care and set new benchmarks for both operational and scientific excellence in clinical research.
Also Read: Streamline Healthcare Names Danny Gladden as CCO
“DCRI’s proven infrastructure for trial operations including site activation, patient pre-screening, enrollment, retention and study management along with our deep expertise in cardiometabolic and renal disease, enables us to design and execute trials that are both scientifically robust and operationally agile,” said Dr. Adrian Hernandez, executive director, DCRI. “Together with IQVIA, whose global scale and technology and AI capabilities enable efficient execution, we are expanding access to diverse patient populations and ensuring that our studies deliver meaningful results for sponsors, regulators, and most importantly, patients.”
Additional benefits of this strategic collaboration include:
- Expanded access to representative patient populations across 56 countries and more than 3,000 sites.
- Extended impact of thought leadership beyond immediate stakeholders bolstered by the involvement of DCRI clinical and data science and biostatistics faculty in presenting results.
- Leveraging of DCRI’s track record of pioneering research in GLP-1 receptor agonists and SGLT2 inhibitors, as well as IQVIA’s advanced analytics, electronic health records and real-world data in trial design and execution.
Source: Businesswire